Company: CALX
Filing Date: 2025-03-27
Form Type: DEF 14A
Source: 0001406666-25-000011
Chunk: 36

Company: CALIX, INC
Filing Date: 2025-03-27
Form: DEF 14A
Chunk 36
---
 annual basis, each director and executive officer is obligated to complete a director and officer questionnaire which requires disclosure of any transactions with us in which the director or executive officer, or any member of his or her immediate family, have a direct or indirect material interest. We also review our relationship with any entity employing a director or on which the director currently serves as a member of the board. After review of all relevant transactions or relationships between each director, or any of his or her immediate family members, and Calix, its senior management and its independent registered public accounting firm, the Board has affirmatively determined that all of Calix’s current directors, and Mr. Berry, a nominee for Class III director, are independent directors within the meaning of the applicable NYSE standards, except for Mr. Russo, Calix’s chairman, and Mr. Weening, Calix's president and chief executive officer. All of the committees of our Board are comprised entirely of directors determined by the Board to be independent within the meaning of the NYSE standards and applicable SEC regulations.

<div align='center'>26</div>

#### PROPOSAL NO. 2
<div align='center'>APPROVAL OF THE CALIX, INC. FOURTH AMENDED AND RESTATED 2019 EQUITY INCENTIVE AWARD PLAN</div>

We are asking our stockholders to approve the amendment and restatement of the Calix, Inc. Fourth Amended and Restated 2019 Equity Incentive Award Plan (as amended and restated, the “2019 Plan”) to increase the number of shares authorized and available for issuance under the 2019 Plan by 4,000,000 shares, resulting in an increase to the total shares authorized and available for issuance under the 2019 Plan from 619,731 to 4,619,731 and to increase the calendar year limit on the grant date fair value of equity-based awards made to our non-employee directors from $750,000 to $1,500,000. Our Board, upon recommendation of the Talent and Compensation Committee, approved the increase by 4,000,000 shares of the shares authorized for issuance in March 2025 and to increase the calendar year limit on the grant date fair value of equity-based awards made to our non-employee directors from $750,000 to $1,500,000, subject to stockholder approval. The 2019 Plan was originally adopted by our Board in March 2019 and approved by stockholders in May 2019.